NRAS is mutated in ∼30% of cutaneous melanomas (Akbani et al., 2015) (Fig. 4), mostly at the Q61 residue in the switch II region (Fig. 1) that abolishes RAS GTPase activity and, thus, results in constitutive activation. The gene discussed is NRAS; the disease is cutaneous melanoma.